Overview

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

Status:
COMPLETED
Trial end date:
2024-06-19
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ; VX-548) and its metabolite along with its safety and tolerability, in healthy participants.
Phase:
PHASE1
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated